•			•		- 10103)
	C	ERTIFICATE OF MAILING				
•	espondence is being deposited washington, D.C. 20231 on this de	ith the United States Postal Service ate.	as first class	mail in an	envelope addressed to:	
Typed or Printed Name	Donna Macedo					
Signature	DI Men	cedo	. #	_Date	1/16/02	
INFORMATION DISCLOSURE STATEMENT	J	Attorney Docket	SMAR-014			
		First Named Inventor	Salari et al. 09/852,424			
		Application Number				ב
	Confirmation No.	5001			2	
Address to:		Filing Date	05/09/01			62/ n na1
Commissioner for Pater Washington, D.C. 2023		Group Art Unit	1646			S
washington, D.C. 2022	, i	Examiner Name	Unassigned			
·		Title	CXCR4 Antagonist Treatment of Hematopoietic Cells			

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged therefor.

By:

Respectfully submitted, **BOZICEVIC, FIELD & FRANCIS LLP**

Date: __/. 16.02

Bret E. Field

Registration No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

F:\DOCUMENT\SMAR (SMA)\014\IDS - BEFORE 1ST OA1.DOC